# Biotech Daily Digest ‚Äî 2025-12-06

**13 items from 2 sources**

## Summary by Source

- Endpoints News: 7 items
- Fierce Biotech: 6 items


## Endpoints News

- **[#ASH25: As one door closes for Regeneron‚Äôs lymphoma bispecific, another reopens](https://endpoints.news/ash25-as-one-door-closes-for-regenerons-lymphoma-bispecific-another-reopens/)**  
  _Sat, 06 Dec 2025 14:30:29 +0000_  
  ORLANDO ‚Äî Regeneron is facing another twist in its roller-coaster ride to win US approval of its lymphoma treatment, odronextamab, after a series of regulatory and manufacturing hurdles.

 Earlier in 2025, the Tarrytown, NY, drugmaker said ...

- **[Bristol Myers expands Breyanzi approval to marginal zone lymphoma](https://endpoints.news/bristol-myers-expands-breyanzi-approval-to-marginal-zone-lymphoma/)**  
  _Fri, 05 Dec 2025 19:17:02 +0000_  
  Bristol Myers Squibb‚Äôs CAR-T therapy Breyanzi has become the first such treatment approved for patients with a rare, slow-growing type of non-Hodgkin lymphoma.

 The drug was approved Thursday for third-line patients with marginal zone lymphoma ...

- **[ACIP drops universal hepatitis B birth dose recommendation](https://endpoints.news/acip-drops-universal-hepatitis-b-birth-dose-recommendation/)**  
  _Fri, 05 Dec 2025 16:52:18 +0000_  
  A panel of CDC vaccine advisors has stopped recommending that all children receive the hepatitis B vaccine at birth, overruling scientific consensus and public health officials who pleaded that there was no grounded rationale for ...

- **[Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protara](https://endpoints.news/denali-drug-hold-intercept-layoffs-capital-raises-for-immatics-capricor-and-protara/)**  
  _Fri, 05 Dec 2025 16:05:30 +0000_  
  Plus, news about Vanda, Hangzhou Highlightll Pharmaceutical and Guard Therapeutics.

 üõë FDA places hold on Denali Pompe drug: The FDA asked the biotech to update its protocol for a Phase 1 of its candidate ...

- **[Rapport shares updated results from Phase 2 study of seizure drug](https://endpoints.news/rapport-shares-updated-results-from-phase-2-study-of-seizure-drug/)**  
  _Fri, 05 Dec 2025 16:02:46 +0000_  
  Rapport Therapeutics shared new data from a mid-stage trial of its seizure drug, saying that it demonstrates consistent efficacy over time and ‚Äúacross the spectrum of disease severity.‚Äù

 The results build on

- **[Biopharma sentiment hit a turning point in October](https://endpoints.news/biopharma-sentiment-hit-a-turning-point-in-october/)**  
  _Fri, 05 Dec 2025 15:51:32 +0000_  
  Inside the two-week stretch that marked a reversal in biopharma sentiment.

 During the two weeks that our biopharma sentiment survey was in the field in mid-October, something unusual happened: The mood of the industry appeared ...

- **[OTR Therapeutics gets $100M from Pfizer Ventures, others to build asset portfolio](https://endpoints.news/otr-therapeutics-gets-100m-from-pfizer-ventures-others-to-build-asset-portfolio/)**  
  _Fri, 05 Dec 2025 15:27:01 +0000_  
  A new biotech has raised $100 million to build a mix of assets from inside and outside China, while developing its own drug candidates.

 The Shanghai-based startup, called OTR Therapeutics, is a new twist on ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out" hreflang="en">'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out</a>](https://www.fiercebiotech.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out)**  
  _Dec 5, 2025 1:19pm_  
  The industry‚Äôs mRNA alliance is demanding steady FDA leadership, warning that the current ‚Äúunprecedented turmoil‚Äù at the agency is eroding Americans' trust and threatening public health.

- **[<a href="https://www.fiercebiotech.com/biotech/encoded-deciphers-path-pivotal-trial-phase-12-dravet-gene-therapy-data" hreflang="en">Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data</a>](https://www.fiercebiotech.com/biotech/encoded-deciphers-path-pivotal-trial-phase-12-dravet-gene-therapy-data)**  
  _Dec 5, 2025 10:22am_  
  Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech on track to start a pivotal study next year.

- **[<a href="https://www.fiercebiotech.com/medtech/natera-buys-foresight-diagnostics-cancer-mrd-deal-worth-450m" hreflang="en">Natera buys Foresight Diagnostics in cancer testing deal worth up to $450M</a>](https://www.fiercebiotech.com/medtech/natera-buys-foresight-diagnostics-cancer-mrd-deal-worth-450m)**  
  _Dec 5, 2025 12:00pm_  
  Natera has closed the transaction, which features an upfront payment of $275 million plus as much as $175 million in milestones tied to revenue and reimbursements.

- **[<a href="https://www.fiercebiotech.com/biotech/markets-thinking-backwards-fdas-1-trial-approval-plan-would-boost-rd-spend-jefferies" hreflang="en">‚ÄòMarket‚Äôs thinking is backwards‚Äô: FDA‚Äôs 1-trial approval plan would boost R&amp;D spend, Jefferies says</a>](https://www.fiercebiotech.com/biotech/markets-thinking-backwards-fdas-1-trial-approval-plan-would-boost-rd-spend-jefferies)**  
  _Dec 5, 2025 10:36am_  
  The FDA‚Äôs reported plan to move toward single-trial approvals has stirred industry concern, but one analyst views the proposal as a catalyst for greater R&D investment in the sector.

- **[<a href="https://www.fiercebiotech.com/medtech/cancer-blood-test-developer-freenome-go-public-330m-spac-deal" hreflang="en">Cancer blood test developer Freenome to go public in $330M SPAC deal</a>](https://www.fiercebiotech.com/medtech/cancer-blood-test-developer-freenome-go-public-330m-spac-deal)**  
  _Dec 5, 2025 10:18am_  
  Backed by an affiliate of Perceptive Advisors and joined by RA Capital, the move includes a commitment of $240 million in equity investments plus about $90 million more held by the SPAC‚Äôs trust fund.

- **[<a href="https://www.fiercebiotech.com/biotech/praxis-claims-efficacy-success-phase-2-seizure-trial-setting-approval-talks-fda" hreflang="en">Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA</a>](https://www.fiercebiotech.com/biotech/praxis-claims-efficacy-success-phase-2-seizure-trial-setting-approval-talks-fda)**  
  _Dec 5, 2025 9:03am_  
  Having already claimed a win for the phase 2 study of its seizure drug, Praxis Precision Medicines is hoping fresh efficacy data will form the backbone of an approval application for its sodium channel inhibitor.
